CTNM Contineum Therapeutics, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$11.49

Period return

-0.76 (-6.20%)

Volume

285.4K

2026-06-05O $12.34 H $12.47 L $11.46 C $11.49MA5 $12.36MA20 $13.34MA60 $13.18MA120 $13.19

6M · 124 barsYahoo Finance · USD2025-12-08 → 2026-06-05

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 05. 15.LowHOLD23 days ago
Morgan Stanley: Equal-Weight
US analyst rating / recommendation change.
2026. 03. 06.LowBUY3 months ago
Baird: Outperform
US analyst rating / recommendation change.
2026. 01. 08.MediumHOLD5 months ago
Morgan Stanley: Equal-Weight
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $22.33 · 6 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.

Sector: Healthcare
Industry: Biotechnology
HQ: San Diego, CA, United States
Fiscal year end: —
Employees: 51
IPO date: —

View details →

2025. 11. 24.LowBUY6 months ago

Baird: Outperform